Generic placeholder image

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Research Article

Real-world Utilisation of the Rivastigmine Transdermal Patches Accompanying the Use of Risk Minimisation Tools in Patients with Dementia

Author(s): Fritjof Reinhardt, Nikolaos Scarmeas, Rajesh Karan, Uday K. Veldandi, Sunil Modali*, Krishna Duvvuri and Rashid K. Pathan

Volume 18, Issue 4, 2021

Published on: 08 September, 2021

Page: [273 - 282] Pages: 10

DOI: 10.2174/1567205018666210716120540

open access plus

Abstract

Background: Transdermal patches are convenient to use, especially in Rotkreuz ZG Rotkreuz ZG patients with Alzheimer’s disease (AD)-associated dementia. However, various identified risks of errors in administering the patches cannot be disregarded. Patient Reminder Cards (PRCs, included a Medication record sheet [MRS]) have been recently introduced as a risk minimisation tool to prevent incorrect patch use (IU).

Objectives: This study aimed to assess the effectiveness of PRCs to prevent IU and to investigate the dose titration pattern of rivastigmine patches in a real-world setting.

Methods: This multinational, observational, 11-month study included patients with AD currently using rivastigmine patches (4.6 mg/day, 9.5 mg/day, 13.3 mg/day) accompanied by a caregiver. Study outcomes were IU, including multiple patch use (MPU), incorrect patch placement, other IUs, perceived usefulness of the PRCs, and titration patterns of the patches.

Results: Of the total 614 patients included, most were aged ≥ 65 years and had mild-to-moderate AD. Before and during the study, 27.7% and 18.0% of patients reported IU, respectively. Most patients used MRS, and 73.5% rated it ‘helpful’ and reported lower rates of IU than those who reported it ‘not helpful’ (13.9%-16.5% vs. 20.2%). Overall, 141 patients had dose titrations, with 75.8% being up-titrated from 4.6 mg/day to 9.5 mg/day after a mean duration of 58 days. Safety findings were consistent with the established profile for the rivastigmine patch.

Conclusion: PRC was effective as a risk minimisation tool in limiting the inappropriate use of rivastigmine patches. The majority of patients requiring dose-change were up-titrated to 9.5 mg/day patches.

Keywords: Rivastigmine patch, inappropriate medication use, multiple patch use, Alzheimer’s dementia, neurodegenerative conditions, corticobasal syndrome.

Next »
[1]
Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol 2012; 19(9): 1159-79.
[http://dx.doi.org/10.1111/j.1468-1331.2012.03784.x] [PMID: 22891773]
[2]
WHO. The epidemiology and impact of dementia Available from: https://www.who.int/mental_health/neurology/dementia/dementia_thematicbrief_epidemiology.pdf [Accessed on 27th Sep, 2019
[3]
Prince M. World Alzheimer Report 2015 Alzheimer's Disease International Available from: https://www.alz.co.uk/research/worldalzheimerreport2015summary.pdf [Accessed on 18th Dec, 2019
[4]
van der Flier WM, Scheltens P. Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry 2005; 76(5): v2-7.
[http://dx.doi.org/10.1136/jnnp.2005.082867] [PMID: 16291918]
[5]
Prizer LP, Zimmerman S. Progressive support for activities of daily living for persons living with dementia. Gerontologist 2018; 58(1): S74-87.
[http://dx.doi.org/10.1093/geront/gnx103]
[6]
Mehta M, Adem A, Sabbagh M. New acetylcholinesterase inhibitors for Alzheimer’s disease. Int J Alzheimers Dis 2012; 2012: 728983.
[http://dx.doi.org/10.1155/2012/728983] [PMID: 22216416]
[7]
Ngo J, Holroyd-Leduc JM. Systematic review of recent dementia practice guidelines. Age Ageing 2015; 44(1): 25-33.
[http://dx.doi.org/10.1093/ageing/afu143] [PMID: 25341676]
[8]
Bailey JA, Lahiri DK. A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer’s disease. J Neurochem 2010; 112(4): 843-53.
[http://dx.doi.org/10.1111/j.1471-4159.2009.06490.x] [PMID: 19912467]
[9]
Bailey JA, Ray B, Greig NH, Lahiri DK. Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 2011; 6(7): e21954.
[http://dx.doi.org/10.1371/journal.pone.0021954] [PMID: 21799757]
[10]
Ballard CG, Greig NH, Guillozet-Bongaarts AL, Enz A, Darvesh S. Cholinesterases: Roles in the brain during health and disease. Curr Alzheimer Res 2005; 2(3): 307-18.
[http://dx.doi.org/10.2174/1567205054367838] [PMID: 15974896]
[11]
Characteristics. SoP. Exelon 46 mg/24h transdermal patch 2018. Available from: https://wwwmedicinesorguk/emc/product/1185/smpc#gref.
[12]
Khoury R, Rajamanickam J, Grossberg GT. An update on the safety of current therapies for Alzheimer’s disease: Focus on rivastigmine. Ther Adv Drug Saf 2018; 9(3): 171-8.
[http://dx.doi.org/10.1177/2042098617750555] [PMID: 29492246]
[13]
Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s disease. Int J Geriatr Psychiatry 2007; 22(5): 485-91.
[http://dx.doi.org/10.1002/gps.1806] [PMID: 17407176]
[14]
Su J, Liu Y, Liu Y, Ren L. Long-term effectiveness of rivastigmine patch or capsule for mild-to-severe Alzheimer’s disease: A meta-analysis. Expert Rev Neurother 2015; 15(9): 1093-103.
[http://dx.doi.org/10.1586/14737175.2015.1068120] [PMID: 26289489]
[15]
Seibert J, Tracik F, Articus K, Spittler S. Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice. Neuropsychiatr Dis Treat 2012; 8: 141-7.
[PMID: 22536070]
[16]
Ueda K, Katayama S, Arai T, et al. Efficacy, safety, and tolerability of switching from oral cholinesterase inhibitors to rivastigmine transdermal patch with 1-step titration in patients with mild to moderate Alzheimer’s disease: A 24-week, open-label, multicenter study in Japan. Dement Geriatr Cogn Disord Extra 2019; 9(2): 302-18.
[http://dx.doi.org/10.1159/000501364] [PMID: 31572426]
[17]
Alva G, Grossberg GT, Schmitt FA, Meng X, Olin JT. Efficacy of rivastigmine transdermal patch on activities of daily living: Item responder analyses. Int J Geriatr Psychiatry 2011; 26(4): 356-63.
[http://dx.doi.org/10.1002/gps.2534] [PMID: 21312297]
[18]
Bernabei R, Rossini PM, Di Cioccio L, et al. Compliance and caregiver satisfaction in alzheimer’s disease: Results from the AXEPT study. Dement Geriatr Cogn Disord Extra 2012; 2(1): 418-32.
[http://dx.doi.org/10.1159/000338228] [PMID: 23139687]
[19]
Heneka N, Shaw T, Rowett D, Lapkin S, Phillips JL. Exploring factors contributing to medication errors with opioids in australian specialist palliative care inpatient services: A multi-incident analysis. J Palliat Med 2018; 21(6): 825-35.
[http://dx.doi.org/10.1089/jpm.2017.0578] [PMID: 29473770]
[20]
Lövborg H, Holmlund M, Hägg S. Medication errors related to transdermal opioid patches: Lessons from a regional incident reporting system. BMC Pharmacol Toxicol 2014; 15: 31.
[http://dx.doi.org/10.1186/2050-6511-15-31] [PMID: 24912424]
[21]
Lampert A, Seiberth J, Haefeli WE, Seidling HM. A systematic review of medication administration errors with transdermal patches. Expert Opin Drug Saf 2014; 13(8): 1101-14.
[http://dx.doi.org/10.1517/14740338.2014.926888] [PMID: 24921682]
[22]
Ali TB, Schleret TR, Reilly BM, Chen WY, Abagyan R. Adverse effects of cholinesterase inhibitors in dementia, according to the pharmacovigilance databases of the United-States and Canada. PLoS One 2015; 10(12): e0144337.
[http://dx.doi.org/10.1371/journal.pone.0144337] [PMID: 26642212]
[23]
Lövborg H, Jönsson AK, Hägg S. A fatal outcome after unintentional overdosing of rivastigmine patches. Curr Drug Saf 2012; 7(1): 30-2.
[http://dx.doi.org/10.2174/157488612800492717] [PMID: 22663954]
[24]
Suzuki Y, Kamijo Y, Yoshizawa T, Fujita Y, Usui K, Kishino T. Acute cholinergic syndrome in a patient with mild Alzheimer’s type dementia who had applied a large number of rivastigmine transdermal patches on her body. Clin Toxicol (Phila) 2017; 55(9): 1008-10.
[http://dx.doi.org/10.1080/15563650.2017.1329536] [PMID: 28594244]
[25]
EMA. Committee for Medicinal Products for Human Use Exelon (rivastigmine). 2013.
[26]
Good Publication Practices of ISPE 2007. Available from: https://ispe.org/publications/guidance-documents [Accessed on 27th Sep, 2019
[27]
Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration. Epidemiology 2007; 18(6): 805-35.
[http://dx.doi.org/10.1097/EDE.0b013e3181577511] [PMID: 18049195]
[28]
Niu H, Álvarez-Álvarez I, Guillén-Grima F, Aguinaga-Ontoso I. Prevalence and incidence of Alzheimer’s disease in Europe: A meta-analysis. Neurologia 2017; 32(8): 523-32.
[http://dx.doi.org/10.1016/j.nrl.2016.02.016] [PMID: 27130306]
[29]
Birks JS, Chong LY, Grimley Evans J. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2015; 9: CD001191.
[PMID: 26393402]

© 2022 Bentham Science Publishers | Privacy Policy